Our Mission
Our Story
Search
Corporate Social Responsibility | Boehringer Ingelheim US
Boehringer Ingelheim has a strong and longstanding commitment to improving the health of people and animals, both around the world and in local communities.
new_health_insurance_marketplace_coverage_options_and_your_health_coverage.pdf
Championing minds for generations both in and out of the workplace
Boehringer Ingelheim is now certified for Mental Health America’s (MHA) Bell Seal for Workplace Mental Health.
Why role models matter for black veterinarians: One doctor's story
Why role models matter for black veterinarians: One doctor's story
Kobe
The Kobe Pharma Research Institute takes part in the global research and development activities for human pharmaceuticals.
Meet our Team
Meet Our Team
retinal_health_dr_infographic_0.pdf
Partnering-Oral-Health.pdf
Economist Impact Report: Rethinking Mental Health Care
Partnering-Outlook-Animal-Health-2024-USA.pdf
Prescription digital therapeutics and mental health care
Partnering-Animal-Health.pdf
Public Health Cost from AF.pdf
Access to Healthcare Strategy PDF
Partnering-Mental-Health-Disorders_0.pdf
Partnering-Mental-Health-Disorders.pdf
retinal-health-partnering-interests.pdf
Boehringer Ingelheim and King’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophrenia
Boehringer Ingelheim and King’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophrenia
Yamagata
With its location in the Yamagata prefecture (Higashine), this site focuses on the production & packaging of human pharmaceuticals for the Japanese market.
U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)
U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)
Our Culture of Caring: Volunteering
At BI we are committed to improving the health and well-being of people & animals. We encourage & support employee volunteer activities.
Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders
Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders
Depression
Depression
Fighting COVID-19 | COVID-19 | Boehringer Ingelheim US
Read more on how Boehringer Ingelheim's work in developing vaccinations for animals has led us to support the pharma industry with the COVID-19 pandemic.